Memantine Grindeks

Memantine Hydrochloride, the active ingredient in Memantine Grindeks, is an NMDA receptor antagonist presented as an oral tablet for oral administration. It is indicated for the management of moderate to severe Alzheimer’s disease, helping to improve cognition and daily functioning in adult patients.

GNH USA supplies Memantine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, offering consistent quality, regulatory documentation, and reliable logistics for global healthcare providers.

Memantine Grindeks is employed in the management of Alzheimer’s disease, a progressive neurodegenerative disorder in which excessive NMDA‑receptor activity contributes to neuronal injury.

Alzheimer’s disease (moderate to severe): improves cognition, functional abilities, and overall clinical status in patients. Alzheimer’s disease (mild to moderate): may provide modest benefit in slowing cognitive decline.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue - Confusion - Hypertension

Serious or Rare Side Effects: - Severe allergic reactions (rash, swelling, anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Seizures - Cardiac arrhythmias - Hepatic dysfunction

Memantine should be used with clinical monitoring and awareness of patient‑specific factors. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic disease: monitor liver enzymes regularly. - Concomitant CNS depressants: use caution as additive sedation may occur. - History of seizures: assess risk before initiating therapy. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Memantine may interact with several drug classes; awareness helps avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine or other NMDA antagonists: additive neuro‑psychiatric effects. - Strong CYP450 inducers (e.g., rifampin, carbamazepine): may reduce memantine plasma levels.

Moderate Interactions (Monitor Closely): - Antacids or alkaline agents: can increase urinary pH and affect renal clearance. - CNS depressants (benzodiazepines, opioids): may enhance sedation. - Diuretics: monitor electrolytes as shifts may alter memantine excretion.